Zolgensma European Union - Finnish - EMA (European Medicines Agency)

zolgensma

novartis europharm limited  - onasemnogene abeparvovec - lihassärky, spinaali - muut lääkkeet liikuntaelinten sairauksien häiriöihin - zolgensma on tarkoitettu hoitoon:potilaat, joilla 5q selkärangan lihasten surkastumista (sma), jossa on bi-alleeliset mutaatio smn1-geenin ja kliininen diagnoosi sma tyyppi 1, orpatients kanssa 5q sma, jossa on bi-alleeliset mutaatio smn1-geenin ja jopa 3 kopiota smn2-geeni.

Libmeldy European Union - Finnish - EMA (European Medicines Agency)

libmeldy

orchard therapeutics (netherlands) bv - atidarsagene autotemcel - leukodystrophy, metachromatic - muut hermoston huumeet - libmeldy is indicated for the treatment of metachromatic leukodystrophy (mld) characterized by biallelic mutations in the arysulfatase a (arsa) gene leading to a reduction of the arsa enzymatic activity:in children with late infantile or early juvenile forms, without clinical manifestations of the disease,in children with the early juvenile form, with early clinical manifestations of the disease, who still  have the ability to walk independently and before the onset of cognitive decline.

Fuxien vet 1000 mg/g inhalaatiohöyry, neste Finland - Finnish - Fimea (Suomen lääkevirasto)

fuxien vet 1000 mg/g inhalaatiohöyry, neste

vetpharma animal health, s.l. - isoflurane - inhalaatiohöyry, neste - 1000 mg/g - isofluraani

Abecma European Union - Finnish - EMA (European Medicines Agency)

abecma

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastiset aineet - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Breyanzi European Union - Finnish - EMA (European Medicines Agency)

breyanzi

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastiset aineet - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Upstaza European Union - Finnish - EMA (European Medicines Agency)

upstaza

ptc therapeutics international limited - eladocagene exuparvovec - aminohappoaineenvaihdunta, synnynnäiset virheet - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.

LeukoScan European Union - Finnish - EMA (European Medicines Agency)

leukoscan

immunomedics gmbh - sulesomabia - osteomyelitis; radionuclide imaging - diagnostiset aineet - tämä lääkevalmiste on tarkoitettu vain diagnostiseen käyttöön. leukoscania käytetään diagnostiseen kuvantamiseen määrittämiseksi sijainnista ja laajuudesta infektio/tulehdus luun potilailla, joilla epäillään osteomyeliittiä, mukaan lukien potilaat, joilla on diabeettinen jalka haavaumat. leukoscania ei ole käytetty diagnosoida osteomyeliitti potilailla, joilla on sirppisoluanemia.

Cefotaxim Mip Pharma 1 g injektio-/infuusiokuiva-aine liuosta varten Finland - Finnish - Fimea (Suomen lääkevirasto)

cefotaxim mip pharma 1 g injektio-/infuusiokuiva-aine liuosta varten

mip pharma gmbh - cefotaxime sodium - injektio-/infuusiokuiva-aine liuosta varten - 1 g - kefotaksiimi

Cefotaxim Mip Pharma 2 g injektio-/infuusiokuiva-aine liuosta varten Finland - Finnish - Fimea (Suomen lääkevirasto)

cefotaxim mip pharma 2 g injektio-/infuusiokuiva-aine liuosta varten

mip pharma gmbh - cefotaxime sodium - injektio-/infuusiokuiva-aine liuosta varten - 2 g - kefotaksiimi

Cefepim MIP Pharma 1 g injektio/infuusiokuiva-aine, liuosta varten Finland - Finnish - Fimea (Suomen lääkevirasto)

cefepim mip pharma 1 g injektio/infuusiokuiva-aine, liuosta varten

mip pharma gmbh - cefepime - injektio/infuusiokuiva-aine, liuosta varten - 1 g - kefepiimi